Home＞BUSINESS
Shionogi, UMN Pharma Conclude Capital Alliance; Tie Up in Infectious Disease Field(Nov.2.2017)
Shionogi and the biotech startup UMN Pharma on October 31 announced a capital investment and business alliance agreement. Under the agreement, UMN Pharma will allocate 600,000 shares of common stock and a first issuance of convertible bonds with stock acquisition rights to Shionogi, which is expected to invest around 1.6 billion yen for the acquisition ...
(LOG IN FOR FULL STORY)
-
- JAK Inhibitor Battle for Atopic Dermatitis Intensifying, 1st Japan Filing Might Be Near Oct.17
- Eisai Seals Latin America Pact for Belviq Oct.17
- Teva Takeda Launches Voluntary Recall for Taxotere Generics Oct.17
- Chugai’s Satralizumab Cuts Relapse Risk of Neuromyelitis Optica Spectrum Disorder Oct.16
- Ono Joins GHIT Fund as 21st Funding Partner Oct.16
- JAK Inhibitor Battle for Atopic Dermatitis Intensifying, 1st Japan Filing Might Be Near(Oct.17)
- MHLW Lifts Contraindications for Combined Statin-Fibrate Use in Renal-Impaired Patients(Oct.17)
- Eisai Seals Latin America Pact for Belviq(Oct.17)
- Teva Takeda Launches Voluntary Recall for Taxotere Generics(Oct.17)
- ADR Victim Relief Claims Fall below 1,500 in FY2017: MHLW(Oct.17)
